

**FORM 39A [(SEE RULE 150 E (f) UNDER THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)**

Generic Name : Adrenaline Injection IP

Sample Name : Adrenaline Injection IP

Submitted By : M/s Meghalayan Medical Drugs and Services Limited  
(MMDSL)  
New Colony Shillong, DHS Laitumkhrah, Office of the  
Managing Director, MMDSL East Khasi Hills District  
Meghalaya Shillong (Assam) 793003 District Meghalaya  
Shillong (Assam) 793003

Format No : [REDACTED]  
Mfg. Lic.No. : [REDACTED]

Report No. : [REDACTED]

Date of Receipt : 18/04/2024

Report Date : 03/05/2024

Period of Analysis : 18/04/2024-03/05/2024

Stability Condition :

Mfd. By : NS

Supplied By : NS

Ref.No. : NS

<b>Batch No.</b>	<b>Mfg. Date</b>	<b>Exp. Date</b>	<b>Batch Size</b>	<b>Sample Qty.</b>
MMDSL/QC-0185	02/2024	01/2025	NS	50 Ampoules

**RESULTS OF ANALYSIS**

Reference to Protocol : I.P.-2022  
Description : Clear colourless liquid filled in amber coloured glass ampoules

<b>Test Parameters</b>	<b>Results</b>	<b>Limit</b>
------------------------	----------------	--------------

Identification :

(A) by HPLC : Complies -

(B) by Chemically : Complies -

(C) by Chemically : Complies -

Appearance of solution : Complies -

Nominal Volume : 1.0 ml -

Average fill Volume : 1.0 ml -

Uniformity of Volume : Within limit -

pH : 3.12 : 2.8 to 3.6

Noradrenaline (by HPLC) : 0.017% : NMT 1.0%

Sterility : Complies -

Assay (by HPLC) : Each ml contains:

<u>Particulars</u>	<u>Result</u>	<u>Claim</u>	<u>Lower</u>	<u>Upper</u>	<u>Method</u>
Adrenaline Tartrate eq. Adrenaline	0.992 mg	1.0 mg	0.9 mg	1.15 mg	IP-2022

\*\*\*End of Report\*\*\*

Remark: In the opinion of the undersigned the sample referred to above is of standard quality as defined in the Act